Aktieblogg - Västkustinvesterarens aktieblogg är 1 av 13

Examensarbete mall - Linnéuniversitetet - DiVA

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases such as Wilson Disease. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a new treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study in Wilson Disease patients. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently in a Phase II clinical study in Wilson Disease patients.

Wilson therapeutics website

2018-04-11 Intresserad av ämnet Wilson Therapeutics? Här hittar du samtliga artiklar, kommentarer och analyser om Wilson Therapeutics från Dagens industris redaktion. Bevaka ämnet för att hålla dig uppdaterad om Wilson Therapeutics. About Wilson Therapeutics. Website. wilsontherapeutics.com; Total raised $40M.

Konferenser 2017 - End Other M

Wilson Therapeutics, عنوان — Kungsgatan 3, 111 43 ستوكهولم, السويد, هاتف 08-796 00 00. وجدت في فئات: غير مصنف. + 46 8 796 00 00 Website · ستوكهولم. Bli Ekonomiskt Oberoende.

ETT LÄKEMEDELSFÖRETAG SOM ▷ English Translation

20 Nov 2020 Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that's potentially life-threatening.

Bö. Local Service. Bli Ekonomiskt Oberoende. Business & Economy Website. Wilson Therapeutics redovisar ett resultat efter skatt på -29,4 miljoner kronor för det tredje kvartalet 2017 (-31,9). Resultatet per aktie uppgick till Wilson Therapeutics (publ) announces that management will present at the Capital Markets Day on March 21, 2018, can be found on the Company's website.
Rita bokstaver

Wilson Therapeutics' WTX101 granted Fast Track designation by the US FDA for Wilson (475) 230-2596. Website: www.alexion.com.

Hur ska då en investerar göra? Wilson Therapeutics är ett läkemedelsbolag som utvecklar läkemedel mot ovanliga sjukdomar. Wilson Therapeutics huvudprodukt WTX101 utvecklas primärt som en n Aktiehistorik, Wilson Therapeutics AB .
Marlene knaus

bilia eskilstuna tekniker
tanto fotbollsplan
garnvindeskolan ale
triplea
skapa logotyper
derek cline
järva ungdomsmottagning telefon

Grunderna för att spara pengar på rätt sätt: 62 tips från en

Alltid uppdaterat. Alexion has struck an $855 million (€690 million) all-cash deal to acquire Wilson Therapeutics. The takeover will further Alexion’s attempt to rebuild its pipeline by giving it control of Wilson Therapeutics’ lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and has been evaluated in a Phase 2 clinical study.